

Narrative Review

The Burning Necessity for Establishing National Guidelines - Side Effects of Lipid Lowering Drugs and Difficulty of using High Intensity Statins in Pakistani Population

Noor Dastgir^{1*} and Wafa Qaisar²

¹Department of Cardiology, Allama Iqbal Medical College, Jinnah Hospital, Lahore, Pakistan

²Department of Medicine, Akhter Saeed Medical College, Farooq Hospital Lahore, Pakistan

Lipid lowering strategy has been widely used in both the primary as well as the secondary prevention of atherosclerotic cardiovascular disease, particularly in managing patients who are either diagnosed with ischemic heart disease or stroke or face great susceptibility to developing these complications as a result of risk factors like diabetes, hypertension, sedentary lifestyle and so on [1,2].

The mechanism of action of Statins is by inhibition of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase which is the rate-limiting step in cholesterol synthesis [3]. Statins hence have a great impact on the lipid metabolism and play a vital role in prevention of atherosclerotic complications [4]. They reduce LDL-C, Total cholesterol, and Triglyceride levels; slightly increase HDL-C levels [5]; and are also thought to have anti-inflammatory and other plaque stabilization effects, referred to as their pleiotropic properties [6].

***Corresponding author:** Noor Dastgir, Department of Cardiology, Allama Iqbal Medical College, Jinnah Hospital, Lahore, Pakistan, Tel: +92 3215555189; E-mail: noordastgir@gmail.com

Citation: Dastgir N, Qaisar W (2021) The Burning Necessity for Establishing National Guidelines - Side Effects of Lipid Lowering Drugs and Difficulty of Using High Intensity Statins in Pakistani population. J Angiol Vasc Surg 6: 059.

Received: January 07, 2021; **Accepted:** February 05, 2021; **Published:** February 12, 2021

Copyright: © 2021 Dastgir N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The updated guideline on the use and dosing of statins was issued in 2013 by the American College of Cardiology (ACC) and the American Heart Association (AHA) where a classification was devised categorizing therapy into low, medium and high intensity therapy stating fixed doses, and clear indications as to which patients would be benefitted by which group [7,8].

High intensity statin therapy hopes to achieve LDL reductions of more than 50% of the baseline and mainly includes Atorvastatin (40-80mg) and Rosuvastatin (20-40mg) [9]. While all the benefits of lipid lowering therapy cannot be emphasized upon enough, it does bring out the question of challenges in compliance to treatment regimens comprised of such high doses owing to the side effects being experienced by the patients [10,11].

Statins may cause widespread systemic effects like hepatotoxicity, type 2 diabetes, cataract, polyneuropathy, memory loss, behavioral changes and, rarely, headache, gastrointestinal disturbance, rash etc [12].

Most common concerning consequences of statin therapy include musculoskeletal system involvement in the form of myopathy and tendinopathy that may present with muscle aches (myalgias) and sometimes even leading to muscle breakdown (rhabdomyolysis) causing elevated creatinine kinase levels with a pathophysiology not completely understood [13-16].

Studies done previously have reported that muscle and tendon related side effects were most commonly noticed in patients treated with rosuvastatin. The onset of myalgias may be variable ranging from a few weeks after treatment initiation to years. Older age, female gender, individual patient genetics and comorbid conditions like hypertension, diabetes and hypothyroidism are all factors that may increase the prevalence of such effects along with processes at molecular level like the CYP mediated statin metabolism and various drug-drug interactions [17,18].

In view of this, FDA recommends lowest effective dose of statins to reduce statin-associated myopathies and other untoward outcomes accompanying their use [19].

Inter-racial differences in response to statins have been previously reported [20]. Asian patients have been seen to have a mounted response compared to the Caucasian population due to differences in ethnicity and the genetic make-up affecting the metabolism [21]. In one such study, it was seen in the Japanese population that a lower dose of statins demonstrated similar relative risk reduction of cardiovascular events to a higher dose of statins in Western patients [22,23]. In fact, the maximum dose of atorvastatin in clinical practice was 40 mg per day in Japan, while the dose is 80 mg per day in the United States [24]. Most adverse effects of statins are dose related and in a directly proportional relationship [25].

It is important to understand that Pakistani patients may have a lower threshold for tolerance of statin therapy while at the same time, they may require perhaps a lower dose to achieve target levels of LDL. In a study conducted at Agha Khan University, it was concluded that even an alternate day regimen may have similar clinical benefits to standard daily dosing but with better tolerance and compliance [25].

Several studies have been done internationally studying the difficulties health care providers face while ensuring adherence to high dose statin therapy. We wish to explore the possibility of establishing these interracial differences in response to statin therapy, both in achieving the therapeutic goals as well the occurrence of intolerable side effects that may lead to discontinuation of medication despite clear clinical benefits. Hence it is important to emphasize the need of developing national guidelines keeping in mind our population regarding statin therapy.

References

1. Harrison TN, Scott RD, Cheetham TC, Chang SC, Hsu JY, et al. (2018) Trends in statin use 2009-2015 in a large integrated health system: pre- and post-2013 ACC/AHA guideline on treatment of blood cholesterol. *Cardio-vasc Drugs Ther* 32: 397-404.
2. European Association for Cardiovascular Prevention & Rehabilitation; Reiner Z, Catapano AL, De Backer G, Graham I, et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias . The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 32: 1769-1818.
3. Hess CN, Low Wang CC, Hiatt WR (2018) PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. *Annu Rev Med* 69: 133-145.
4. Rosenson RS (2004) Statins in atherosclerosis: Lipid-lowering agents with antioxidant capabilities. *Atherosclerosis* 173: 1-2.
5. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. *Science* 292: 1160-1164.
6. Oesterle A, Laufs U, Liao JK (2017) Pleiotropic effects of statins on the cardiovascular system. *Circulation research* 120: 229-243.
7. Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, et al. (2016) Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
8. Garcia-Gil M, Blanch J, Comas-Cufi M, Daunis-i-Estadella J, Bolibar B, et al. (2016) Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical records. *J Clin Lipidol* 10: 134-142.
9. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). *Eur Heart J* 33: 1635-1701.
10. Jacobson TA (2014) NLA task force on statin safety-2014 update. *J Clin Lipidol* 8: 1-4.
11. Krüger K, Leppkes N, Gehrke-Beck S, Herrmann W, Algharably EA, et al. (2018) Improving long-term adherence to statin therapy: a qualitative study of GPs' experiences in primary care. *British Journal of General Practice* 68: 401-407.
12. Beltowski J, Wojcicka G, Jamroz-Wisniewska A (2009) Adverse effects of statins-mechanisms and consequences. *Current drug safety* 4: 209-28.
13. Scott RS, Lintott CJ, Wilson MJ (1991) Simvastatin and side effects. *New Zealand Medical Journal* 104: 493-495.
14. Cham S, Evans MA, Denenberg JO, Golomb BA (2010) Statin-associated muscle-related adverse effects: a case series of 354 patients. *Pharmacotherapy* 30: 541-553.
15. Nikolic D, Banach M, Chianetta R, Luzzu LM, Pantea Stoian A, et al. (2020) An overview of statin-induced myopathy and perspectives for the future. *Expert Opin Drug Saf* 19: 601-615.
16. Golomb BA, Evans MA (2008) Statin adverse effects : A review of the literature and evidence for a mitochondrial mechanism. *Am J Cardiovasc Drugs* 8: 373-418.
17. Thompson PD, Panza G, Zaleski A, Taylor B (2016) Statin-associated side effects. *J Am Coll Cardiol* 67: 2395-410.
18. Stoes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, et al. (2015) Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J* 36: 1012-1022.
19. Murakami H, Sakaeda T, Kadoyama K, Okuno Y (2013) Gender effects on statin-associated muscular adverse events: an analysis of the FDA AERS database. *Pharmacol Pharm* 4: 340-346.
20. Naito R, Miyauchi K, Daida H (2017) Racial differences in the cholesterol-lowering effect of statin. *J Atheroscler Thromb* 24: 19-25.
21. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, et al. (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. *Clin Pharmacol Ther* 78: 330-334.
22. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, et al. (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet* 368: 1155-1163.
23. Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, et al. (2018) Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. *Circulation Journal* 82: 1008-1016.
24. Naito R, Miyauchi K, Daida H (2017) Racial Differences in the Cholesterol-Lowering Effect of Statin. *J Atheroscler Thromb* 24: 19-25.
25. Abdul Muhammad Z, Ahmad T, Baloch N (2019) Can alternate-day Statin regimen minimize its adverse effects on muscle and tendon? A systematic review. *J Pak Med Assoc* 69: 1006.



- Advances In Industrial Biotechnology | ISSN: 2639-5665
- Advances In Microbiology Research | ISSN: 2689-694X
- Archives Of Surgery And Surgical Education | ISSN: 2689-3126
- Archives Of Urology
- Archives Of Zoological Studies | ISSN: 2640-7779
- Current Trends Medical And Biological Engineering
- International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X
- Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276
- Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292
- Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370
- Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594
- Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X
- Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562
- Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608
- Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879
- Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397
- Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751
- Journal Of Aquaculture & Fisheries | ISSN: 2576-5523
- Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780
- Journal Of Biotech Research & Biochemistry
- Journal Of Brain & Neuroscience Research
- Journal Of Cancer Biology & Treatment | ISSN: 2470-7546
- Journal Of Cardiology Study & Research | ISSN: 2640-768X
- Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943
- Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771
- Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844
- Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801
- Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978
- Journal Of Cytology & Tissue Biology | ISSN: 2378-9107
- Journal Of Dairy Research & Technology | ISSN: 2688-9315
- Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783
- Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X
- Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798
- Journal Of Environmental Science Current Research | ISSN: 2643-5020
- Journal Of Food Science & Nutrition | ISSN: 2470-1076
- Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X
- Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566
- Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485
- Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662
- Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999
- Journal Of Hospice & Palliative Medical Care
- Journal Of Human Endocrinology | ISSN: 2572-9640
- Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654
- Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493
- Journal Of Light & Laser Current Trends
- Journal Of Medicine Study & Research | ISSN: 2639-5657
- Journal Of Modern Chemical Sciences
- Journal Of Nanotechnology Nanomedicine & Nanobiotechnology | ISSN: 2381-2044
- Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X
- Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313
- Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400
- Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419
- Journal Of Obesity & Weight Loss | ISSN: 2473-7372
- Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887
- Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052
- Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X
- Journal Of Pathology Clinical & Medical Research
- Journal Of Pharmacology Pharmaceutics & Pharmacovigilance | ISSN: 2639-5649
- Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670
- Journal Of Plant Science Current Research | ISSN: 2639-3743
- Journal Of Practical & Professional Nursing | ISSN: 2639-5681
- Journal Of Protein Research & Bioinformatics
- Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150
- Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177
- Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574
- Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060
- Journal Of Surgery Current Trends & Innovations | ISSN: 2578-7284
- Journal Of Toxicology Current Research | ISSN: 2639-3735
- Journal Of Translational Science And Research
- Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193
- Journal Of Virology & Antivirals
- Sports Medicine And Injury Care Journal | ISSN: 2689-8829
- Trends In Anatomy & Physiology | ISSN: 2640-7752

Submit Your Manuscript: <https://www.heraldopenaccess.us/submit-manuscript>